A new trial is testing whether a specialist medical tampon could help improve the early diagnosis of ovarian cancer. The ...

If you have recurrent or platinum-resistant ovarian cancer, your doctor may recommend folate receptor alpha (FRα) testing. If you test positive for elevated levels of FRα (expressed on 75 percent or ...

Premenopausal women would benefit from a significantly more accurate diagnostic pathway for ovarian cancer, as a new study ...

You might hear about your risk of ovarian cancer through an aunt, mother, sister or grandmother. For some, there are no signs of hereditary cancer in the family, but genetic testing still reveals a ...

A new ovarian cancer surveillance test is now being offered to women with an inherited risk of the disease, marking a significant development in care. University College London Hospitals NHS ...

FDA approved a PD-L1 companion test to identify patients with ovarian, fallopian tube or primary peritoneal cancer who may receive first-line Keytruda. The U.S. Food and Drug Administration (FDA) has ...

Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with low-grade serous ovarian cancer (LGSOC), according to a study. The ...

Only 23.3% of ovarian cancer patients receive BRCA testing, leading to higher treatment costs and advanced therapy lines. Non-White and low-income patients face increased financial toxicity, ...

Age is the primary risk factor for ovarian cancer.

Ovarian cancer spreads fast by recruiting the body’s own protective cells to clear the way—and that secret alliance may finally be its undoing.

As is often the case with cancer treatments, many patients are able to benefit from therapy for a time. Tumor activity ...